NICE adds Baraclude to hepatitis B list
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's Baraclude (entecavir) has been confirmed as a treatment option for patients in the national health service in England and Wales with chronic hepatitis B. The National Institute for health and Clinical Excellence's final analysis found the product to be clinically effective at an acceptable cost in both HBeAg-positive and HBeAg-negative patients, despite earlier reservations about its cost-effectiveness in the latter group (Scrip Online, April 10th, 2008).